Table 2.
Outcome = Symptom Change (Ending - Starting Symptom) | |||||
---|---|---|---|---|---|
(1) | (2) | (3) | (4) | (5) | |
Panel A: Product Type, omitted category = flower | |||||
Concentrate | 0.194** | 0.080 | |||
(0.076) | (0.212) | ||||
Edible | 0.340*** | ||||
(0.105) | |||||
Tincture | 0.498*** | ||||
(0.117) | |||||
Topical | −0.216 | ||||
(0.355) | |||||
Panel B: Subspecies, omitted category = hybrid | |||||
C. indica | −0.103** | −0.057 | |||
(0.041) | (0.083) | ||||
C. sativa | 0.096* | 0.195 | |||
(0.055) | (0.121) | ||||
Panel C: Combustion Method, omitted category = joint | |||||
Pipe | −0.061 | −0.004 | |||
(0.084) | (0.194) | ||||
Vape | 0.051 | 0.051 | |||
(0.092) | (0.210) | ||||
Panel D: THC and CBD, omitted categories = THC < 10% and CBD < 1% | |||||
THC 10–19% | −0.215* | −0.220* | |||
(0.117) | (0.134) | ||||
THC 20–34% | −0.235** | −0.315*** | |||
(0.112) | (0.121) | ||||
THC 35%+ | −0.252** | −0.342** | |||
(0.126) | (0.166) | ||||
CBD 1–9% | −0.089 | −0.026 | |||
(0.121) | (0.126) | ||||
CBD 10–34% | 0.038 | 0.079 | |||
(0.105) | (0.092) | ||||
CBD 35%+ | −0.222 | −0.241 | |||
(0.209) | (0.227) | ||||
Starting Symptom Level | −0.704*** | −0.721*** | −0.726*** | −0.709*** | −0.717*** |
(0.028) | (0.031) | (0.032) | (0.056) | (0.063) | |
Constant | 0.588*** | 0.691*** | 0.719*** | 0.909*** | 0.850** |
(0.165) | (0.184) | (0.212) | (0.340) | (0.403) | |
Number of sessions | 19,910 | 17,197 | 16,898 | 4,439 | 3,869 |
R-squared | 0.330 | 0.340 | 0.338 | 0.337 | 0.346 |
Number of users | 3,341 | 2,996 | 2,936 | 900 | 787 |
Notes: Regressions control for individual user fixed effects. Concentrate is relative to Flower, C. indica and C. sativa are relative to Hybrid, THC categories are relative to THC 0–9%, CBD categories are relative to CBD 0%, and Pipe and Vape are relative to Joint. Standard errors are clustered at the user level (shown in parentheses). ***p < 0.01, **p < 0.05, *p < 0.1.